Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Desoxyn

Related Products

Hot Products

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Name

Desoxyn

EINECS N/A
CAS No. 7632-10-2 Density 0.907g/cm3
PSA 12.03000 LogP 2.22790
Solubility N/A Melting Point 134-135 °C
Formula C10H15N Boiling Point 215.5°Cat760mmHg
Molecular Weight 149.236 Flash Point 86.8°C
Transport Information N/A Appearance N/A
Safety Poison by ingestion, intraperitoneal, subcutaneous, and intravenous routes. A powerful central nervous system stimulant. When heated to decomposition it emits toxic fumes of NOx. See also BENZEDRINE. Risk Codes N/A
Molecular Structure Molecular Structure of 7632-10-2 (DL-Methamphetamine) Hazard Symbols N/A
Synonyms

(+/-)-N-Methylamphetamine;Divk1c_000988;

Article Data 44

Desoxyn Chemical Properties

Chemical Name: DL-Methamphetamine
IUPAC NAME: N-Methyl-1-phenylpropan-2-amine
CAS No.: 7632-10-2
Molecular Formula: C10H15N
Molecular Weight: 149.23 g/mol
Density: 0.907 g/cm3 
Flash Point: 86.8 °C
Boiling Point: 215.5 °C at 760 mmHg
Following is the structure of Desoxyn (7632-10-2):
The chemical synonymous of Desoxyn (7632-10-2) are DL-Desoxyephedrine ; Benzeneethanamine, N,a-dimethyl- (9CI) ; dl-Methamphetamin ; Ephedrine, deoxy- ; N,a-Dimethylbenzeneethanamine ; N,a-Dimethylphenethylamine

Desoxyn History

In November 1943, Abbott Laboratories submitted a New Drug Application (NDA) to the Drug Division at the U.S. Food and Drug Administration (FDA) for Desoxyn. Abbott requested approval for narcolepsy, mild depression, postencephalitic parkinsonism, chronic alcoholism, cerebral arteriosclerosis, and hay fever. The NDA included review articles from academic journals, case histories from physicians, and a 3-page testimonial from a patient with narcolepsy. All these requests were accepted, and the drug was approved in December, 1944. All of these indication approvals were eventually removed. The only two approved marketing indications remaining for methamphetamine are for ADHD and the short-term management of exogenous obesity, although the drug is clinically established as effective in the treatment of narcolepsy.A sustained-release formulation of methamphetamine in the form of a plastic-matrix tablet, named the Desoxyn Gradumet, was introduced after the standard Desoxyn formulation was introduced. Abbott discontinued production of the Desoxyn Gradumet in the Fall of 1999, citing "manufacturing difficulties" as the reason for its discontinuation. The 5 milligram immediate release tablet is the only formulation presently available.In a joint sale for US$40 million, Abbott sold their rights to Desoxyn and Tranxene to Ovation Pharmaceuticals. Able Labs produced the first generic formulation of methamphetamine hydrochloride in 2004, until the company went out of business the following year.

Desoxyn Uses

 Desoxyn (7632-10-2) is considered to have significant abuse potential.It is considered to not have any greater risk of misuse and addiction than its close relative amphetamine, although methamphetamine causes a higher degree of euphoria, a lesser degree of adverse physical reactions, and a longer lasting duration of effects than amphetamine.

Desoxyn Toxicity Data With Reference

1.    

orl-rat LDLo:70 mg/kg

    AEPPAE    Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 195 (1940),647.
2.    

ipr-rat LDLo:32 mg/kg

    AEPPAE    Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 195 (1940),647.
3.    

scu-rat LD50:30 mg/kg

    AIPTAK    Archives Internationales de Pharmacodynamie et de Therapie. 159 (1966),442.
4.    

orl-mus LD50:34 mg/kg

    JPETAB    Journal of Pharmacology and Experimental Therapeutics. 131 (1961),115.
5.    

ipr-mus LD50:15 mg/kg

    CPBTAL    Chemical and Pharmaceutical Bulletin. 22 (1974),1459.
6.    

scu-mus LD50:10 mg/kg

    AEPPAE    Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 241 (1961),182.
7.    

ivn-mus LD50:10 mg/kg

    27ZIAQ    Drug Dosages in Laboratory Animals-A Handbook C.D. Barnes andL.G. Eltherington,Berkeley, CA.: Univ. of California Press,1965
8.    

scu-cat LDLo:50 mg/kg

    27ZIAQ    Drug Dosages in Laboratory Animals-A Handbook C.D. Barnes andL.G. Eltherington,Berkeley, CA.: Univ. of California Press,1973,158.

Desoxyn Safety Profile

Poison by ingestion, intraperitoneal, subcutaneous, and intravenous routes. A powerful central nervous system stimulant. When heated to decomposition it emits toxic fumes of NOx. See also BENZEDRINE.

Desoxyn Specification

 Desoxyn (7632-10-2) is a psychostimulant drug intended for medical usage in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD),narcolepsy and for the short-term treatment of exogenous obesity.It is currently a Schedule II substance of the Controlled Substances Act in the United States. Drugs that are listed as Schedule II substances, such as methamphetamine, are drugs that are recognized to have a high risk for misuse, physical addiction, and/or psychological addiction, but they still have clinically accepted medical usage, Schedule II drugs are the most restricted of drugs with accepted medicinal use.and it is a potent central nervous system stimulant that acts as a substrate at the norepinephrine, dopamine (DA) and serotonin (5-HT) neurotransmitters, triggering an influx of these neurotransmitters from the cytosol into the trans-synaptic space via a process of 'reverse transport' by the monoamine reuptake transporter proteins (in which methamphetamine molecules are exchanged for endogenous monoamine substrate molecules). The compound also inhibits the reuptake of the transmitters into the pre-synaptic neuron by competing for uptake as substrates for the transporter, causing them to remain in the synaptic cleft longer. The resulting increased levels of dopamine and norepinephrine in these synapses affect neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. While amphetamine and methamphetamine have similar effects on dopamine and noradrenaline release, methamphetamine is a far more effective agonist of serotonin.